Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

(2019) Tri Le et al.   Cancers

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer

(2019) Ayesha Murtuza et al.   CANCER RESEARCH

Honokiol Induces Autophagic Apoptosis in Neuroblastoma Cells through a P53-Dependent Pathway

(2019) Ming-Chung Lin et al.   AMERICAN JOURNAL OF CHINESE MEDICINE

Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets

(2019) Kishore Banik et al.   PHARMACOLOGICAL RESEARCH

Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer

(2019) Fei Cao et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib

(2019) Yiting Li et al.   CANCER

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

(2018) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Toxicology of Magnolol and Honokiol

(2018) Andrea Sarrica et al.   PLANTA MEDICA

BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review

(2018) Xuanzong Li et al.   Targeted Oncology

Mechanisms and Therapy for Cancer Metastasis to the Brain

(2018) Federica Franchino et al.   Frontiers in Oncology

Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy

(2018) Guoqing Qian et al.   CANCER LETTERS

Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3

(2017) S Sengupta et al.   ONCOGENE

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

(2016) Puyu Shi et al.   CANCER LETTERS

Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway

(2016) Jing Pan et al.   Cancer Prevention Research

Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor–stromal cross-talk

(2016) Courey Averett et al.   CARCINOGENESIS

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer

(2016) Azusa Tanimoto et al.   CLINICAL CANCER RESEARCH

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

(2015) M. J. Niederst et al.   CLINICAL CANCER RESEARCH

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors

(2015) Michael Juchum et al.   DRUG RESISTANCE UPDATES

mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation

(2015) Junghui Koo et al.   MOLECULAR AND CELLULAR BIOLOGY

Overcoming Resistance to Targeted Therapy for Lung Cancer

(2015) Ramaswamy Govindan   NEW ENGLAND JOURNAL OF MEDICINE

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

(2015) Alfredo Tartarone et al.   Therapeutic Advances in Respiratory Disease

The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis

(2013) Hui Ren et al.   CANCER LETTERS

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

(2013) J. Remon et al.   CANCER TREATMENT REVIEWS

Neuro-Modulating Effects of Honokiol: A Review

(2013) Anna Woodbury et al.   Frontiers in Neurology

Thr 163 Phosphorylation Causes Mcl-1 Stabilization when Degradation Is Independent of the Adjacent GSK3-Targeted Phosphodegron, Promoting Drug Resistance in Cancer

(2012) Shanna K. Nifoussi et al.   PLoS One

Therapeutic applications of compounds in the Magnolia family

(2011) Young-Jung Lee et al.   PHARMACOLOGY & THERAPEUTICS

Honokiol Crosses BBB and BCSFB, and Inhibits Brain Tumor Growth in Rat 9L Intracerebral Gliosarcoma Model and Human U251 Xenograft Glioma Model

(2011) Xianhuo Wang et al.   PLoS One

The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis

(2008) S. M. Raja et al.   MOLECULAR CANCER THERAPEUTICS